EGFR Exon 20 Mutation
Associated Genetic Biomarkers
EGFR Exon 20 Mutation is present in 1.07% of AACR GENIE cases, with lung adenocarcinoma, conventional glioblastoma multiforme, glioblastoma, non-small cell lung carcinoma, and bladder urothelial carcinoma having the greatest prevalence .
EGFR Exon 20 Mutation serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 20 Mutation as an inclusion criterion, 1 is phase 2 (1 open).
Trials with EGFR Exon 20 Mutation in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
Poziotinib is the most frequent therapy in trials with EGFR Exon 20 Mutation as an inclusion criteria .
Significance of EGFR Exon 20 Mutation in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients with EGFR Exon 20 Mutation present in 5.41% of all non-small cell lung carcinoma patients .
EGFR Exon 20 Mutation is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 20 Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.